Migraine Research Reagents

Migraine is a complex neurovascular disorder affecting over 1 billion people globally, driven by trigeminovascular system activation, cortical spreading depression, and neuropeptide release (CGRP, PACAP). The clinical success of anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) and gepants (small molecule CGRP receptor antagonists) has validated CGRP as the central therapeutic target in migraine prevention.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Migraine Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key migraine and headache disorder research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

CGRP & CGRP Receptor (CALCRL/RAMP1) — CGRP released from trigeminal neurons drives meningeal vasodilation and neurogenic inflammation in migraine. Anti-CGRP antibodies and recombinant CGRP/CALCRL proteins support receptor pharmacology studies and migraine biomarker assay development.
→ Browse CGRP antibodies & proteins

PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) — PACAP-38 infusion triggers migraine attacks in susceptible individuals. Anti-PACAP antibodies (AMG 301 class) are in clinical development. Research-grade anti-PACAP antibodies and recombinant proteins support trigeminovascular signaling studies.
→ Browse PACAP antibodies & proteins

5-HT1B/1D Receptors — Serotonin 5-HT1B/1D receptors are the targets of triptans, the gold-standard acute migraine treatment. Anti-5-HT receptor antibodies support receptor distribution mapping and triptan mechanism-of-action research.

References

1. Ashina M. Migraine. N Engl J Med. 2020;383(19):1866-1876. DOI

2. Edvinsson L, et al. CGRP as the target of new migraine therapies. Nat Rev Neurol. 2018;14(6):338-350. DOI

3. Goadsby PJ, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123-2132. DOI

4. Schytz HW, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132(1):16-25. DOI